Study wrapper · #479
Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.
Editor's note
This meta-analysis of 24 randomised trials (2,158 adults) assessed incretin therapies, GLP-1 receptor agonists and emerging dual agonists, in metabolic dysfunction-associated steatotic liver disease. Compared with placebo, the pooled estimates showed reductions in the liver enzymes ALT and AST and in liver fat, with greater enzyme improvement versus insulin and improved non-invasive fibrosis markers. Notably, steatohepatitis resolution was greater than placebo but not insulin, and effects on histologic fibrosis remained inconclusive with wide confidence intervals for liver fat. The abstract does not name specific agents, so this reads as class-level evidence for the family that includes semaglutide and tirzepatide. Benefits appeared larger in patients with diabetes. For readers, this supports a biochemical and imaging benefit signal in fatty liver disease while leaving the harder endpoint, fibrosis reversal, unproven; the authors call for larger, longer trials.
Plain-language abstract
This analysis combined 24 randomised trials with about 2,158 adults who had fatty liver disease linked to metabolic problems. Incretin medicines, the drug family that includes semaglutide and tirzepatide, were compared with placebo, insulin, or oral diabetes drugs. Compared with placebo, they lowered liver enzymes and liver fat and improved some non-invasive scar-tissue markers, with benefits often greater in people who also had diabetes. However, improvement in actual liver scarring seen on biopsy was not clearly established. The specific drugs were not named in the summary, so this reflects the drug class overall. The authors conclude the medicines help liver blood tests and fat, but longer, larger studies are needed to confirm effects on scarring.